Skip to main content
OpenTrials
Completed

NCT Number: NCT06333964

A Study to Evaluate the Efficacy and Safety of AST-001 in ASD Children

1. Study purpose: To demonstrate the superiority of AST-001 compared to placebo in improving core symptoms of autism spectrum disorder (ASD) in children with ASD. 2. Background: ASD is a neurodevelopmental disorder characterized by deficits in social communication and social interaction as well as restricted, repetitive patterns of behavior, interests, or activities. There are no approved medicines to treat the core symptom of ASD. Although these drugs and other psychotropic medications are associated with side effects, the use of psychotropic drugs to treat associated psychiatric comorbidities is common. AST-001 is developed to treat the core symptom of ASD. 3. Design: Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 clinical trial followed by an Open-Label Extension Treatment Period

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Autism Spectrum Disorder Child Development Disorders, Pervasive Mental Disorders Neurodevelopmental Disorders

Age range

2 year–7 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Soon Chun Hyang University Hospital Cheonan, Cheonan, Chungcheongnam-do, South Korea

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Those who meet the criteria of diagnostic and statistical manual of mental disorder (DSM)-5 during screening
  • During screening period, individuals who are diagnosed with ASD through ADI-R assessment
  • Subject with a CGI-S score of 4 or higher as a result of Clinical Global Impression(CGI) evaluation during baseline visit(visit 2)
  • Subject or/and legally authorized representative voluntarily agreed to participate in this clinical trial and provided their informed consent by signing the written consent form
  • In case of subjects who were receiving non-pharmacological therapy at the time of screening, the non-pharmacological therapy lasted at least 3 months prior to participation in screening and is expected to be sustainable during this clinical trial
  • Subject whose legally authorized representative is able to participate in the provision of reliable information about the subject's condition, execute all scheduled site visits, oversee IP administration, fully understand and speak Korean, and conduct survey evaluation regarding the subject

Exclusion criteria

  • At the time of screening, subject has the medical history, concomitant condition, or surgical history
  • During the screening period, uncontrolled medical conditions,
  • During the screening period, display of severe self-harm or injury to others that requires medical treatment, determined by investigator
  • At the time of screening, weight over 60kg
  • Inappropriate to participate in the trial determined by investigator

Treatment and study plan

AST-001

Drug

AST-001, PO bid for 24weeks (dosage according to weight range)

Placebo of AST-001

Drug

Placebo of AST-001, PO bid for 12 weeks + AST-001, PO bid for 12 weeks (dosage according to weight range)

Primary outcomes

  1. K-VABS-II (Korean-Vineland Adaptive Behavior Scale-II)

    Time frame: Baseline, 12week, 24week

Secondary outcomes

  1. CGI (Clinical Global Impression)

    Time frame: Baseline, 4week, 8week, 12week, 18week, 24week

  2. SRS-2 (Social Responsiveness Scale-2)

    Time frame: Baseline, 4week, 12week, 24week

  3. K-PSI-4-SF (Korean-Parenting Stress Index-4th Edition Short Form)

    Time frame: Baseline, 12week, 24week

Sponsors and collaborators

Lead sponsor

Astrogen, Inc.

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of AST-001 Followed by an Open-Label Extension Treatment Period in Children With Autism Spectrum Disorder

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Mar 27, 2024
Registry last updated
Feb 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.